Candriam Equities L Biotechnology Class I EUR Hedged CapRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 25.6 | -8.7 | -0.1 | 2.5 | 1.0 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 25/04/2024 | EUR 1926.82 | |
Day Change | -1.38% | |
Morningstar Category™ | Other Equity | |
ISIN | LU1006082199 | |
Fund Size (Mil) 25/04/2024 | USD 1441.67 | |
Share Class Size (Mil) 25/04/2024 | EUR 20.54 | |
Max Initial Charge | - | |
Ongoing Charge 17/02/2023 | 0.80% |
Investment Objective: Candriam Equities L Biotechnology Class I EUR Hedged Cap |
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund as set out below and defined in the section entitled Risk factors in the Prospectus. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Rudi Van den Eynde 06/04/2000 | ||
Linden Thomson 29/02/2024 | ||
Inception Date 04/12/2015 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Candriam Equities L Biotechnology Class I EUR Hedged Cap | 29/02/2024 |
|
|
Top 5 Holdings | Sector | % |
Vertex Pharmaceuticals Inc | Healthcare | 6.89 |
Regeneron Pharmaceuticals Inc | Healthcare | 6.42 |
Amgen Inc | Healthcare | 5.95 |
Gilead Sciences Inc | Healthcare | 5.74 |
AstraZeneca PLC | Healthcare | 3.64 |
Increase Decrease New since last portfolio | ||
Candriam Equities L Biotechnology Class I EUR Hedged Cap |